Business context and reporting period
Syntec Optics Holdings, Inc. manufactures integrated optics and photonics components and systems, serving defense, medical, consumer, and communications markets. This filing reports unaudited results for the three months ended March 31, 2024, compared with the three months ended March 31, 2023. The request metadata says “2023 Q3,” but the filing itself is for the quarter ended March 31, 2024.
The November 2023 business combination was accounted for as a reverse recapitalization, with Legacy Syntec as the accounting acquirer. The financial statements therefore principally reflect Legacy Syntec’s historical results.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $6.26 million | $6.88 million |
| Gross profit / margin | $0.71 million / 11% | $1.71 million / 25% |
| Operating income (loss) | ($1.41 million) | $0.19 million |
| Net income (loss) | ($1.21 million) | $0.05 million |
| Operating cash flow | ($0.29 million) | $0.53 million |
| Adjusted EBITDA (non-GAAP) | ($0.67 million) | $1.00 million |
At March 31, 2024, cash was $1.68 million; working capital was approximately $3.84 million and the current ratio was 1.39. Total assets were $24.62 million, total liabilities $12.77 million, and stockholders’ equity $11.85 million. The company had $5.44 million drawn on its $10 million line of credit, leaving $4.6 million available, and $3.45 million in total term and mortgage debt before unamortized issuance costs. The line’s weighted-average borrowing rate was 7.63%; the company reported compliance with debt covenants.
Investing cash outflow was $0.10 million, mainly capital spending; financing cash outflow was $0.09 million. Cash declined by $0.47 million during the quarter. The cash flow statement reports cash interest paid of $157,895.
Material changes versus the prior comparable period
- Revenue declined 9.1%. Management attributed the decrease mainly to lower sales across medical, consumer, and defense markets, partly offset by communications growth.
- Communications revenue rose to $2.06 million from $0.37 million; defense revenue fell to $1.19 million from $2.38 million, medical to $1.77 million from $2.45 million, and consumer to $1.24 million from $1.68 million.
- Cost of goods sold rose 7.3% despite lower revenue, reflecting higher payroll and subcontractor costs. Gross margin fell to 11% from 25%.
- General and administrative expense increased 39.3% to $2.11 million. Management cited higher professional fees, advertising, insurance, and research and development expense.
- Interest expense increased to $0.16 million from $0.13 million. The company moved from a small profit to a $1.21 million net loss.
- Operating cash flow turned negative despite a $1.73 million reduction in accounts receivable; higher inventory and the net loss were among the cash-flow factors.
Outlook, risks, contingencies, and unusual items
The filing provides no quantitative revenue, earnings, or cash-flow guidance. Management describes opportunities in defense, communications, and sensing, including new products and potential bolt-on acquisitions, but these are forward-looking plans, not committed forecasts.
Key risks include customer and product mix variability, dependence on a small number of customers, end-market and macroeconomic demand, competition, supplier and material availability, interest-rate exposure, and the ability to fund operations and meet debt requirements. Three customers generated 53% of quarterly revenue; their receivables were approximately $3.13 million at quarter-end. Inventory increased to $6.47 million, including $6.01 million of work in process, while the obsolescence reserve rose to $0.52 million.
Management concluded that disclosure controls and procedures were not effective at March 31, 2024 due to seven identified material weaknesses, including insufficient formal control documentation and accounting resources, untimely reconciliations, weaknesses in cost cut-off and related-party identification, contingent earnout valuation controls, and IT general and cybersecurity controls. The company said it is instituting remediation measures. Management reported no material litigation and no subsequent event requiring adjustment or disclosure.
Important facts for investors to verify
- Confirm the reporting-period mismatch: the filing is for March 31, 2024, despite the request metadata identifying 2023 Q3.
- Track remediation and independent testing of the disclosed material weaknesses in financial reporting and IT controls.
- Assess whether weaker gross margins, higher operating costs, and negative operating cash flow persist in later quarters.
- Monitor customer concentration, communications-market growth, and the elevated work-in-process inventory and obsolescence reserve.
- Review borrowing availability, interest costs, covenant headroom, and scheduled debt maturities; the filing says covenants were met at quarter-end.
- Consider potential dilution: 14.1 million warrants are outstanding at an $11.50 exercise price, alongside 26 million contingent earnout shares.